Endoscopic application of dextranomer/hyaluronic acid copolymer in the treatment of vesico-ureteric reflux after renal transplantation

BJU Int. 2011 Jun;107(12):1967-72. doi: 10.1111/j.1464-410X.2010.09792.x. Epub 2010 Nov 8.

Abstract

Objective: • To evaluate the success of endoscopic dextranomer/hyaluronic acid copolymer (DHAC) application in the treatment of patients with recurrent urinary tract infections (UTIs) and vesico-ureteric reflux (VUR) into the transplanted graft after renal transplantation.

Patients and methods: • Between January 2008 and April 2009, 19 patients with recurrent UTIs presented VUR proven by voiding cystourethrography. • To correct VUR of the transplanted ureter, DHAC was injected endoscopically using hydrodistention technique. • Pre- and postoperative serum creatinine levels, the number of pre- and postoperative UTIs, postoperative complications and reflux resolution rate were recorded. The mean follow-up was 6.5 months.

Results: • The average number of UTIs was reduced significantly from 4.89 (range 2-14) to 1.31 (range 0-4) on pre- and postoperative follow-up, respectively, of 6 months (P < 0.001). The success rate increased from 57.9% after the first injection to 78.9% after the second injection. • The remaining four patients with residual VUR received long-term low dose antibiotic prophylaxis. In total, two (10.5%) patients developed increasing creatinine levels postoperatively as a result of distal ureteral obstruction, and temporary urinary drainage was necessary in both patients.

Conclusions: • DHAC appears to be an efficient and minimal invasive method for treating VUR after renal transplantation with respect to short-term success. • Further investigation with a larger group of patients and longer follow-up is needed to evaluate the prolonged effect, as well as any potential side effects.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Biocompatible Materials / administration & dosage*
  • Dextrans / administration & dosage*
  • Female
  • Humans
  • Hyaluronic Acid / administration & dosage*
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Secondary Prevention
  • Treatment Outcome
  • Ureteroscopy*
  • Urinary Tract Infections / etiology
  • Urinary Tract Infections / prevention & control*
  • Vesico-Ureteral Reflux / etiology
  • Vesico-Ureteral Reflux / therapy*
  • Young Adult

Substances

  • Biocompatible Materials
  • Dextrans
  • dextranomer-hyaluronic acid copolymer
  • Hyaluronic Acid